Pfizer reports positive data from late-stage BEACON CRC trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Results from the phase III BEACON CRC trial show significant improvements in overall survival and objective response rates for the BRAFTOVI Triplet and BRAFTOVI Doublet combination (BRAFTOVI and cetuximab), compared to cetuximab plus irinotecan-containing regimens (Control), and provide analysis of the efficacy and safety of the BRAFTOVI Triplet compared to the BRAFTOVI Doublet.

The trial evaluates the combination of Braftovi (encorafenib), Mektovi (binimetinib), and cetuximab (Braftovi Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer, following one or two lines of therapy.

Pfizer sponsors the trial.

BRAFTOVI Triplet showed a median OS of 9.0 months, compared to 5.4 months for Control. An improved ORR of 26% was observed in BRAFTOVI Triplet compared to 2% for Control.

These data were presented Sept. 30 at ESMO.

The company expects to submit the results of the trial for marketing approval in the United States in Q4 2019.

Table of Contents

YOU MAY BE INTERESTED IN

U.S. Deputy Secretary for Health and Human Services, Andrea Palm, and Sweden's Minister for Health Care, Acko Ankarberg Johansson, signing the agreement. Credit: Joel Apelthun/Government Offices of SwedenThe United States and Sweden signed an agreement to step up collaborations in science and technology by focusing on cancer research.

Login